Tag : Biologics

Latest News

武田在TAK-062 (Kuma062)治療乳糜瀉1期研究結果出爐後收購PvP Biologics

Newsemia
日本大阪–(BUSINESS WIRE)–(美國商業資訊)–試驗中藥物TAK-062 (Kuma062)治療控制不良的乳糜瀉1期機制驗證研究結論出爐後,武田藥品工業株式會社(TSE:4502/NYSE:TAK)(「武田」)宣布收購PvP Biologics, Inc.。TAK-062可能是同級最佳的高效價超級麩質酶(一種蛋白質,可降解所攝取的麩質),經電腦設計,用於治療乳糜瀉,乳糜瀉是一種嚴重的自體免疫性疾病,患者攝取麩質會導致小腸炎症和損傷。此項1期研究調查TAK-062在健康志願者和乳糜瀉患者中的安全性和耐受性。在健康志願者中研究TAK-062能否降解所攝取的麩質。武田計畫將1期研究資料提交給即將召開的醫學大會進行呈報。 武田胃腸病治療領域部門主管Asit Parikh M.D.博士表示:「許多乳糜瀉患者透過遵循無麩質飲食來控制症狀,但那些持續出現重度症狀的患者缺乏治療方法。PvP Biologics的工作表明,TAK-062是一種高度針對性的治療藥物,可望變革乳糜瀉的治療標準。我們現在正利用我們深厚的胃腸病專長來推展TAK-062和TAK-101臨床研究,這兩種藥物的作用 Source link...
Latest News

Samenvatting: Takeda verwerft PvP Biologics na resultaten van een fase 1-studie van TAK-062 (Kuma062) voor de behandeling van coeliakie

Newsemia
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) (‘Takeda’) kondigde aan dat het PvP Biologics, Inc. heeft overgenomen na de conclusie van...
Latest News

Takeda adquire PvP Biologics após os resultados de um estudo de Fase 1 do TAK-062 (Kuma062) para o tratamento da doença celíaca

Newsemia
OSAKA, Japão–(BUSINESS WIRE)–A Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) anunciou que adquiriu a PvP Biologics, Inc. após a conclusão de um estudo de prova do...
Latest News

Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer

Newsemia
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the completion of a supplemental Biologics License...
Latest News

NantHealth’s Eviti Connect Data Shows Recycling of Chemotherapy and Biologics for Advanced CRC Patients More Common Than Switching to Drug Regimens with Alternative Mechanism of Action

Newsemia
SAN FRANCISCO–(BUSINESS WIRE)–NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced new real-world data on treatment patterns for patients with advanced colorectal...
Biology

Immatics Implements Genedata Biologics® into Proprietary T-Cell Receptor Discovery and Engineering XCEPTOR® Platform

Newsemia
BASEL, Switzerland (PRWEB) November 12, 2019 Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Immatics Biotechnologies , a clinical-stage...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy